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Abstract 
A study was conducted to establish the Relative Response Factors for Zidovudine related impurity C, 
Lamivudine salicylic acid and Zidovudine related impurity B.  A simple and fast isocratic Reverse Phase High 
Performance Liquid Chromatography (RP-HPLC) method was used for the simultaneous determination of the 
related impurities. The method consists of a mobile phase combination of Acetonitrile (HPLC grade) and Buffer 
(0.0680 g of Potassium Dihydrogen Orthophosphate, 0.3 ml of Triethylamine, pH adjusted to 8.0 with 
Orthophosphoric acid to a final volume preparation of 100 ml) in the ratio 10:90 using Phenomenex Luna 5-µm 
C18 (2)-250 x 4.6-mm, 5-µm) as a stationary phase, flow rate of 1.0 mL/min with detection at 270 nm. The RRF 
for Zidovudine related impurity C, Lamivudine salicylic acid and Zidovudine related impurity B were 2.07, 0.13 
and 1.28 respectively.   Results obtained for quantification of the related substance in lamivudine and zidovudine 
single dose oral solid dosage form using the RRF and know standards shows no significant difference at 95 % 
confidence interval. The RRF can therefore be used for the quantification of know related impurities in 
lamivudine zidovudine oral dosage form using the stated chromatographic conditions.  
 
1. INTRODUCTION 
Relative Response Factor (RRF) is an analytical parameter used in chromatographic procedures to control 
impurities/degradants in drug substance and drug product. RRF is used to correct the difference in detector 
response of impurities with analyte peak. RRF is established by slope method with linear range of solutions. 
As per United States Pharmacopoeia (USP) the Relative response factor, is the ratio of the responses of equal 
amounts of the Impurities and the drug substance [1]. It is referred as Correction factor, response factor or relative 
response factor in the USP. 
European Pharmacopoeia refers RRF as correction factor or response factor. The correction factor is reciprocal 
of the response factor. Response Factor is expressed as the sensitivity of a detector for a given substance relative 
to a standard Substance [2].  
As per British Pharmacopoeia (BP) RRF is expressed as Response Factor. The Response Factor is a relative term, 
being the response of equal weights of one substance relative to that of another in the conditions described in the 
test [3].  
RRF are convenience for usage as long as the stated chromatographic condition has been followed with no 
change in parameters. RRF are necessary in impurity testing due to high cost of impurity standards, stability of 
the standards and difficulty in the isolation of this standards for usage. RRF are used in drug purity testing, in 
limit tests, in mass balance test etc. 
The aim of this study is to establish the Relative Response Factors for Zidovudine related impurity C, 
Lamivudine salicylic acid and Zidovudine related impurity B and to compare the recovery using the RRF and 
know standards in lamivudine zidovudine single oral dosage form. 
2. MATERIALS AND METHODS  
2.1 Materials and Reagents: 
Chemicals / Reagents: Acetonitrile (Manufacturer: Fisher Scientific, Batch #: 0803950), USP Purified Water and 
Doubly distilled water. 
Analytical Reference Standards: USP Lamivudine (Lot #: H0H087, Potency: 99.6 %), USP Zidovudine RS (Lot 
#: HOF263, Potency: 99.0 %), USP   Zidovudine Related Compound B RS (Lot #: H0F230, Potency: 100.0 %), 
USP Zidovudine Related Compound C RS (Lot #: GOG181, Potency: 100.0 %), Salicylic acid (Lot #: KOF112), 
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Potency: 99.8 %). Lamivudine (Manufacturer: Shanghai Desano Chemical Co. LTD. China, Lot #: DH010-4-
090405, Potency (OAB): 98.34 %. Zidovudine (Manufacturer: Shanghia Desano Chemical CO Ltd, Lot #: 
DH006-4-090430, Potency (OAB): 100.93 %. 
Pharmaceutical Excipients: Microcrystalline cellulose (Batch #: 0028, Manufacturer: Brahmar Cellulose 
Products PVT Ltd, Solutab (Croscamellose Sodium) (Batch #: 8199/09, Manufacturer: Blanver Farmoquimica 
Ltd, Magnesium Stereate (Batch #: MGSV80097, Manufacturer: Stockbridge International Ltd. Aerosil 
(Colloidal Silicon Dioxide) (Batch #: 132700021, Manufacturer: Biochemie. 
2.2 Instrumentation and Chromatographic conditions. 
Agilent Technologies 1200 series HPLC modules (G1315D, G1315A, G1329A, G1311A, G1332A and organizer, 
with ChemStation data processing software), Sonicator, OHAUS Analytical Balance. Stainless steel column 250 
mm long, 4.6 mm internal diameter filled with Octadecyl silane chemically bonded to porous silica particles of 5 
µm diameter (Phenomenex Luna 5-µm C18 (2)-250 x 4.6-mm, 5-µm). Mobile phase composition was 90(buffer): 
10 Acetonitrile.  Buffer was prepared from 0.0680 g of Potassium Dihydrogen Orthophosphate, 0.3 ml of 
Triethylamine, pH adjusted to 8.0 with Orthophosphoric acid diluted with distilled water to a final volume of 100 
ml. The mobile phase was pumped through the column at a flow rate of 1 mL/minute. The sample injection 
volume was 10 µL. The DAD detector was set at a wavelength of 270 nm for the detection. Column oven was set 
at 30±1 oC and the run time was 25 minutes. 
2.3 Calibration curve for Relative Response Factors (RRF). 
Linearity and Working Concentration range, LOD and LOQ were determine for Zidovudine related impurity C, 
Lamivudine, salicylic acid, Zidovudine and Zidovudine related impurity B by two different analyst. 
A graph of concentration versus response for impurity solutions and standards were plotted. (Concentrations of 
impurity solutions on ‘X’ axis and response or area on ‘Y’ axis). The equation of the calibration curve and 
correlation coefficient were determined. The relative response factor were calculated by both analyst one and 
analyst two. 
Formula for Calculation 
Relative response factor of impurity = [Slope of impurity solution in curve/ Slope of standard solution in curve] 
The precisions were determined using the RRF by evaluating intraday precision and interday precision by 
preparation and analysis of the same sample (all known standards and placebo) in six replicates. This was 
evaluated at various time points (0 (initial), 4, 8, 12, 16, 20 and 24 hours) by the same analyst. Interday precision 
was performed in six replicates at intervals of one day by two different analysts over a period of six days. The 
Percentage contents and relative standard deviation (RSD) were determined in each case. The results were 
subjected to statistical analysis at 95 % confidence interval to determine any significant differences. 
Accuracy was determined using method of spiking. RRF and known impurity Standard concentration were used 
to estimate the impurity in the sample.  Six different amounts corresponding to 80 %, 100 % and 120 % 
concentrations of zidovudine related impurity C, Lamivudine, Lamivudine salicylic acid, Zidovudine, and 
Zidovudine related impurity B working standard and placebo were analysed. The nominal concentrations were 
compared to the actual concentrations using RRF and known standards. The percentage recoveries were noted 
and statistical analysis at 95% confidence interval to determine any significant differences.  
2.5 Application of RRF for the Analysis of Tablet Formulation 
Twenty tablets were weighed, the average weight was noted and powdered. Samples of the powdered tablet 
equivalent to 48 mg of lamivudine and 98 mg of zidovudine were weighed and transferred into a 100 mL 
volumetric flask. 60 mL of the diluent was added and sample sonicated for 5 minutes. Solution was made to 
volume with the diluent. 
Approximaly 0.0124 mg/mL of Zidovudine related compound C, lamivudine, lamivudine salicylic acid, 
zidovudine and Zidovudine related compound B were used for the quantification of the related impurities. 
Recovery using both RRF and Standards were compared using ANOVA at 0.05 significant level. 
 
3. RESULTS AND DISCUSSION  
To develop a relatively simple system, Acetonitrile (HPLC grade) and Triethylamine were used as the only 
organic solvent with buffer (Buffer (0.0680 g of Potassium Dihydrogen Orthophosphate, 0.3 ml of Triethylamine, 
pH adjusted to 8.0 with Orthophosphoric acid to a final volume preparation of 100 ml) 
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Various mobile phase acetonitrile to buffer in the ratios 40:60, 20:80 and 10:90 were used. Mobile composition 
which gave better resolution was observed to be 10(Acetonitrile): 90 (buffer). 
Phenomenex Luna 5-µm C18 (2)-(250 x 4.6-mm, 5-µm) as the stationary phase was adopted and used for the 
analysis.  A wave length of 270 nm was adopted for appreciable peak area for the analyte. A flow rate of 
1mL/min, run time of 25 minutes, injection volume of 10 µL and a column oven temperature of 30 oC were 
adopted for the analysis. 
3.1 Establishment of relative response factor 
Linearity of detector response 
Linearity and Working Concentration range, LOD and LOQ were determine for Zidovudine related impurity C, 
Lamivudine, Lamivudine salicylic acid, Zidovudine and Zidovudine related impurity B by two different analyst.  
The working concentration ranges from 0.0081 mg/mL to 0.0209mg/mL for Zidovudine related impurity C, 
0.0082 mg/mL to 0.0207 mg/mL  for Lamivudine, 0.0085 mg/mL to 0.0206 mg/mL for Lamivudine salicylic 
acid, 0.0081 mg/mL to 0.0205 mg/mL for zidovudine and  0.0086 mg/mL to 0.0207 mg/mL for Zidovudine 
related impurity B. The Correlation co-efficient were observed to be in the range of 0.9975 to 0.9999 
respectively. With regards to residual plot, the residuals were randomly dispersed. 
Fig. 1: Calibration curve for for zidovudine related   Fig. 2: Calibration curve for Lamivudine  
      compound C                                                                                                                                                                                                        
 
Fig 3: Calibration curve for lamivudine salicylic      Fig 4:Calibration curve for zidovudine  
     acid 
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Fig 5: Calibration curve for Zidovudine related compound B 
 
Table 1: Linear regression data, LOQ, LOD and RRF for calibration curves by analyst one 
API 
Zidovudine 
related 
compound C 
Lamivudine 
Lamivudine 
Salicylic 
acid 
Zidovudine 
Zidovudine 
related 
compound B 
Concentration 
range (mg/mL) 
0.0088to 
0.0204 
0.0082 to 
0.0.0204 
0.0087 to 
0.0204 
0.0082 to 
0.0205 
0.0088 to 
0.0204 
slope 36297 23031 3028 17577 22457 
Intercept -7.7729 8.9955 -4.4497 21.843 -12.124 
Correlation 
coefficient 0.9975 0.9971 0.9983 0.9975 0.9999 
LOD 1.12E-04 1.72E-04 1.44E-03 2.88E-04 1.67E-04 
LOQ 3.40E-04 5.21E-04 4.36E-03 8.73E-04 5.07E-04 
RRF 2.07 0.13 1.28 
 
Table 2: Linear regression data, LOQ, LOD and RRF for calibration curves by analyst two 
API 
Zidovudine 
related 
compound C 
Lamivudine 
Lamivudine 
Salicylic 
acid 
Zidovudine 
Zidovudine 
related 
compound B 
Concentration 
range (mg/mL) 
0.0081 to 
0.0209 
0.0083 to 
0.0.0207 
0.0085 to 
0.0206 
0.0081 to 
0.0205 
0.0086 to 
0.0207 
slope 36302 23042 3054 17534 22489 
Intercept -6.0032 95 -5.6756 12.434 -12.565 
Correlation 
coefficient 0.9977 0.9997 0.9983 0.9991 0.9999 
LOD 1.12E-04 1.72E-04 1.43E-03 2.89E-04 1.67E-04 
LOQ 3.40E-04 5.21E-04 4.32E-03 8.75E-04 5.06E-04 
RRF 2.07 0.13 1.28 
 
The % RSD obtained for Intraday and interday precision using RRF for the quantification of related impurities 
were in the range of 0.14 – 0.36 and 0.25 to 0.65 respectively.  The recovery has a high precision since % RSD 
were less than 1.00 %. Analysis of the variance in the recovery both for interday and intraday precision reveals 
no statistically reliable difference since P value obtained were all less than 0.05.  
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Table 3: Recovery for Intraday precision over study period of 24 Hours 
 
Zidovudine related 
compound c 
Lamivudine 
Salicylic acid 
Zidovudine related 
compound B 
Mean 
Recovery (%) 100.34±0.14 99.78±0.36 99.94±0.26 
% RSD 0.14 0.36 0.26 
 
Table 4: Recovery for interday precision by First analyst over a period of Six days. 
  
Zidovudine related 
compound c 
Lamivudine 
Salicylic acid 
Zidovudine related 
compound B 
Mean 
Recovery (%) 99.91±0.25 99.98±0.53 99.94±0.65 
% RSD 0.25 0.53 0.65 
The accuracy of the recovery was determined at three different concentration levels of placebo missed with 
standards. The percentage recovery were found to be in the range of 98.78 % - 100.21 %. Analysis of variance 
performed at 95 % confidence interval reveals that there were no significant differences between the results 
obtained at the various concentration levels. P value observed were greater than 0.05, (p > 0.05). 
Table 6: Mean Recovery at different concentration level. 
Mean 
Recovery 
Zidovudine related 
compound c 
Lamivudine 
Salicylic acid 
Zidovudine related 
compound B 
80% 99.90±0.17 99.65±0.53 100.07±0.56 
100% 99.99±0.64 99.66±0.64 99.70±0.11 
120% 100.21±0.35 98.78.03±0.12 99.78±0.21 
 
The mean recovery of Zidovudine related compound c, Lamivudine Salicylic acid, Zidovudine and Zidovudine 
related compound B in zidovudine lamivudine single oral solid dosage in six replicates were quantified using the 
RRF and known standards. Refer to table 7 and table 8 for percentage recovery. Analysis of variance performed 
at 95 % confidence interval reveals that there were no significant differences between the results obtained at the 
various concentration levels. P value observed were greater than 0.05, (p > 0.05). 
 
Table 7: Mean Percentage of known related impurities in tablet using RRF. 
Zidovudine related 
compound c (%) 
Lamivudine 
Salicylic acid (%) 
Zidovudine related 
compound B (%) 
0.0124±0.000125 0.0034±0.00013 0.0046 ± 0.000021 
 
Table 8: Mean Percentage of known related impurities in tablet using know impurity standards. 
Zidovudine related 
compound c (%)  
Lamivudine Salicylic 
acid (%) 
Zidovudine related 
compound B (%) 
0.0123±0.000133 0.00341±0.00014 0.0045 ± 0.000022 
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4. CONCLUSION  
Relative Response Factor (RRF) is a common analytical parameter frequently used in many chromatographic 
procedures for quantitative or limit tests for impurities because in many cases the corresponding reference 
standards are not available. 
The RRF calculated for Zidovudine related compound c, Lamivudine Salicylic acid, and Zidovudine related 
compound B were observed to be 2.07, 0.13 and 1.28 respectively.  Recovery of impurity mixed with placebo 
and in tablet using both RRF and standards show no significant difference at 95 % confidence interval. The RRF 
calculated can therefore be used to quantify known related substances in lamivudine zidovudine single oral solid 
dosage form. 
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